Investigational drug · Phase 2
Imofinostat
Also called: ABT-301, MPT0E028
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "Imofinostat"
First trial start
2025
Nov 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Imofinostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer (Diagnosis)
- Colorectal Cancer Metastatic
- Colorectal Cancer (CRC)
- Immunotherapy
Approved drugs for the same conditions: Colorectal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Imofinostat" as an intervention, largest first.
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRCRecruiting
Anbogen Therapeutics, Inc.Industry
NCT07244705 · 66 participants (planned) · Start Nov 2025 · Primary completion Apr 2028
Drug: ABT-301; Tislelizumab and 1 more · For: Colorectal Cancer (Diagnosis); Colorectal Cancer Metastatic; Colorectal Cancer (CRC) and 1 more
Sites: Liverpool, Australia; Macquarie Park, Australia; Randwick, Australia · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- MPT0E028, a pan-HDAC inhibitor, ameliorates bleomycin-induced pulmonary fibrosis by promoting AT2-to-AT1 differentiation through the ATM/AMPK/FoxO1 pathway.
Liu CH, Lee HS, Liou JP, et al. · J Biomed Sci 2026
- MPT0E028, a novel pan-HDAC inhibitor, prevents pulmonary fibrosis through inhibition of TGF-β-induced CTGF expression in human lung fibroblasts: Involvement of MKP-1 activation.
Liu CH, Lee HS, Liou JP, et al. · Eur J Pharmacol 2024
- Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells.
Chen M-, Chen C-, Wang J-, et al. · Cell Death Dis 2024
- A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model.
Yeh LY, Fang YT, Lee HS, et al. · Front Med (Lausanne) 2022
- Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
Lin CF, Hsu KC, HuangFu WC, et al. · BMC Pharmacol Toxicol 2020
- Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW, Chang LH, Tu HJ, et al. · Clin Epigenetics 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.